Compare Linde PLC (LIN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs GeneDx Holdings Corp — how do they compare? Linde PLC trades at $481.78 (market cap $226.12B), while GeneDx Holdings Corp trades at $82.03 (market cap $2.44B). The key difference: Linde PLC is far larger — about 92.7× GeneDx Holdings Corp's market cap, and Linde PLC pays a 1.3% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LIN | WGS | |
|---|---|---|
Market Cap | $226.12B | $2.44B |
Sector | Basic Materials | Technology |
52-Week High | $546.64 | $167.51 |
52-Week Low | $389.38 | $34.51 |
Enterprise Value | $249.24B | $2.48B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.46, up 0.51% on the day, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $4.50 exceeding the $4.49 estimate (Zacks Investment Research, 2026-05-01). Revenue growth is steady, and profitability remains robust with a 20.43% net income margin. Analyst sentiment is overwhelmingly positive, with a consensus price target of $553.60.
The outlook for LIN is favorable due to its operational strength and dividend growth, though valuation multiples are elevated. Key risks include rising debt levels and macroeconomic pressures on industrial demand. The stock offers a compelling opportunity for long-term investors seeking quality industrial exposure, but near-term technical weakness may present entry points.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
